MyoKardia (MYOK) Given Daily Media Sentiment Rating of 0.17

News articles about MyoKardia (NASDAQ:MYOK) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MyoKardia earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.4434294640244 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

MyoKardia (NASDAQ MYOK) traded down 1.71% during midday trading on Wednesday, hitting $40.35. The stock had a trading volume of 469,632 shares. The stock’s market cap is $1.43 billion. MyoKardia has a 52 week low of $10.55 and a 52 week high of $49.55. The company has a 50-day moving average price of $43.60 and a 200-day moving average price of $43.60.

MyoKardia (NASDAQ:MYOK) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.04). MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. The firm had revenue of $5.60 million for the quarter, compared to analysts’ expectations of $6.73 million. During the same period in the prior year, the company earned ($0.37) EPS. The firm’s quarterly revenue was up 60.0% on a year-over-year basis. Equities analysts expect that MyoKardia will post ($1.63) EPS for the current year.

A number of equities research analysts have recently weighed in on the company. Credit Suisse Group reissued an “outperform” rating and set a $55.00 target price (up previously from $45.00) on shares of MyoKardia in a report on Tuesday, September 19th. TheStreet raised MyoKardia from a “d+” rating to a “c” rating in a report on Thursday, July 6th. BidaskClub raised MyoKardia from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Cowen and Company lifted their target price on MyoKardia from $28.00 to $56.00 and gave the stock an “outperform” rating in a report on Monday, August 7th. Finally, Zacks Investment Research downgraded MyoKardia from a “hold” rating to a “sell” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. MyoKardia presently has an average rating of “Buy” and an average price target of $55.00.

ILLEGAL ACTIVITY NOTICE: “MyoKardia (MYOK) Given Daily Media Sentiment Rating of 0.17” was first published by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at

In related news, Director Kevin P. Starr sold 75,313 shares of the stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $40.28, for a total transaction of $3,033,607.64. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Anastasios Gianakakos sold 32,988 shares of the stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $15.00, for a total value of $494,820.00. Following the sale, the insider now directly owns 541,151 shares in the company, valued at approximately $8,117,265. The disclosure for this sale can be found here. Insiders have sold a total of 1,786,501 shares of company stock worth $74,371,815 in the last ninety days. Insiders own 33.40% of the company’s stock.

MyoKardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Insider Buying and Selling by Quarter for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply